587 related articles for article (PubMed ID: 18206204)
1. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
2. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
7. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
8. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
Chen X; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
[TBL] [Abstract][Full Text] [Related]
11. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
13. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
[TBL] [Abstract][Full Text] [Related]
14. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks.
Cova L; Wild CP; Mehrotra R; Turusov V; Shirai T; Lambert V; Jacquet C; Tomatis L; Trépo C; Montesano R
Cancer Res; 1990 Apr; 50(7):2156-63. PubMed ID: 2107970
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune response of ducks to duck hepatitis B virus infection.
Vickery K; Cossart Y; Dixon R
J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
[TBL] [Abstract][Full Text] [Related]
16. The effect of surgical immunomodulation on liver inflammation and clearance of DHBV infection.
Vickery K; Tohidi-Esfahani R; Pouliopoulos J; Welschinger R; Dixon R; Deva A; Cossart Y
J Med Virol; 2006 Dec; 78(12):1572-8. PubMed ID: 17063509
[TBL] [Abstract][Full Text] [Related]
17. Delipidation of a hepadnavirus: Viral inactivation and vaccine development.
Cham BE; Vickery K; Tohidi-Esfahani R; Cossart Y
J Virol Methods; 2006 Oct; 137(1):160-3. PubMed ID: 16808980
[TBL] [Abstract][Full Text] [Related]
18. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
19. Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free pekin ducks.
Cullen JM; Marion PL; Sherman GJ; Hong X; Newbold JE
Cancer Res; 1990 Jul; 50(13):4072-80. PubMed ID: 1972346
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].
Tang N; Huang A; Guo S; Qi Z; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):166-8. PubMed ID: 11412394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
